

Sisram Medical Accelerates DAXXIFY Commercialization in Mainland China

Repeat-Purchase Clinics Contribute Over 60% of First-Year Sales, as Partner Network Expansion Exceeds Expectations

HONG KONG, October 28, 2026 -- Sisram Medical Ltd (the “**Company**” or “**Sisram**”, 1696.HK), a global wellness group offering Energy-Based Devices (“EBD”), injectables, and other complementary solutions, today announced the latest commercial milestones for DAXXIFY, its first injectable product launched in Mainland China. Fueled by rising repeat uptake across partner clinics, DAXXIFY is advancing into the next stage of market adoption. The continued build-out of its premium clinic network and development of new channel partnerships further solidify the product’s commercial base and support its expansion trajectory in China.

As at 30 September 2026, DAXXIFY was available at over 630 premium medical aesthetics clinics across Mainland China, exceeding prior disclosed coverage. Clinics placing repeat orders within the product’s launch year contributed more than 60% of total sales, representing an increase of nearly 20 percentage points from 42% as at 30 June 2026. This uptick points to a notable transition from initial trial adoption to regular reordering among core partners. Average sales per clinic have also trended upwards, signaling growing market recognition of DAXXIFY’s value proposition and competitive positioning within the premium medical aesthetics segment.

In tandem with nurturing existing partner relationships, Sisram is rolling out DAXXIFY into new channels and customer cohorts. In September, the Company entered into a strategic partnership with JDH Medical Aesthetics to make DAXXIFY available via its digital platform and self-operated clinics. The parties will jointly implement an end-to-end product traceability system covering supply through to treatment administration. Under an integrated “online ordering, in-clinic delivery” model, the collaboration combines JDH Medical Aesthetics’ digital footprint and offline service network. This enables Sisram to access a wider consumer audience, while strengthening product authenticity safeguards, service standardization and brand exposure.

To elevate professional support for partner clinics, Sisram has launched the PACE-4D Dynamic Facial Assessment System. The framework offers practitioners a standardized, structured facial evaluation methodology across four pillars: pattern, activity, continuity and epidermal quality. By embedding structured facial assessment into physician-patient consultations and personalized treatment planning, PACE-4D helps improve the precision and consistency of clinical outcomes and supports clinics in addressing individual patient requirements.

For the next phase, Sisram will continue to deepen engagement with key medical aesthetics clinics, while refining injection protocols and medical support resources to stimulate end-consumer demand and repeat treatment uptake. Drawing on Alma’s established clinic footprint, the Company will further integrate its EBD and injectables businesses to extend DAXXIFY’s reach and capture cross-selling potential. Concurrently, Sisram will develop combination treatment protocols tailored for the Chinese market, delivering more holistic, customized aesthetic solutions.

“DAXXIFY has delivered encouraging results during its inaugural year in Mainland China, moving from the initial phase of clinic on-boarding to deeper penetration among benchmark clinics and a rising share of repeat-order revenue,” **commented Mr. Jiahong Li, Co-CEO and CFO of Sisram.**

“This traction reflects growing validation of the product’s value, lays a robust commercial groundwork ahead of Prophilo’s upcoming launch in China, and reinforces our confidence in injectables as the Company’s second growth engine. Our priority going forward is to convert this momentum into improved commercialization efficiency and higher-quality growth. We will strengthen key account partnerships and broaden market coverage through multichannel online-offline distribution and Alma’s existing clinic network. We also plan to introduce additional innovative products into China and combine our EBD and injectables expertise to develop differentiated combination regimens adapted to local clinical practices and patient preferences. China remains a core strategic market for Sisram. By pairing our global innovation pipeline with robust local execution and close partner collaboration, we seek to capture further market opportunities and deliver sustainable long-term value for customers and shareholders.”

About Sisram Medical Ltd

Sisram Medical Ltd (1696.HK) is a global leader in medical aesthetic solutions with over 25 years of expertise in Energy-Based Devices (EBD). Built on a legacy of innovation and clinical excellence, the Company’s synergistic ecosystem spans EBD technologies, injectables, diagnostics, and complementary solutions. Serving customers in over 110 countries and regions, Sisram delivers award-winning products that set new standards in safety, efficacy, and personalized aesthetic care for millions of patients worldwide. Majority-owned by Fosun Pharma, Sisram has been listed on the Main Board of the Hong Kong Stock Exchange since September 2017.

For more information, please visit: www.sisram-medical.com.

Forward-Looking Statement

The information communicated in this press release contains certain statements that are or may be forward-looking. These statements typically contain words such as “will,” “expects,” “believes,” “plans” and “anticipates,” and words of similar import. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There may be additional material risks that are currently not considered to be material or of which the Company is unaware. These forward-looking statements are not a guarantee of future performance. Against the background of these uncertainties, readers should not rely on these forward-looking statements. The Company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

For Investor Relations inquiries, please contact:

IR@sisram-medical.com